ES2532942T3 - Listeria obtenida por ingeniería genética y métodos de uso de la misma - Google Patents

Listeria obtenida por ingeniería genética y métodos de uso de la misma Download PDF

Info

Publication number
ES2532942T3
ES2532942T3 ES07752174.8T ES07752174T ES2532942T3 ES 2532942 T3 ES2532942 T3 ES 2532942T3 ES 07752174 T ES07752174 T ES 07752174T ES 2532942 T3 ES2532942 T3 ES 2532942T3
Authority
ES
Spain
Prior art keywords
acta
listeria
polynucleotide
nucleic acid
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07752174.8T
Other languages
English (en)
Spanish (es)
Inventor
Thomas W. Dubensky, Jr.
Justin Skoble
Peter M. Lauer
David N. Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinook Therapeutics Inc
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/396,216 external-priority patent/US20070207171A1/en
Priority claimed from US11/395,197 external-priority patent/US7935804B2/en
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Application granted granted Critical
Publication of ES2532942T3 publication Critical patent/ES2532942T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
ES07752174.8T 2006-03-01 2007-03-01 Listeria obtenida por ingeniería genética y métodos de uso de la misma Active ES2532942T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US77847106P 2006-03-01 2006-03-01
US778471P 2006-03-01
US78457606P 2006-03-21 2006-03-21
US784576P 2006-03-21
US11/396,216 US20070207171A1 (en) 2006-03-01 2006-03-30 Engineered listeria and methods of use thereof
US395197 2006-03-30
US396216 2006-03-30
US11/395,197 US7935804B2 (en) 2006-03-01 2006-03-30 Engineered Listeria and methods of use thereof
PCT/US2007/005457 WO2007103225A2 (en) 2006-03-01 2007-03-01 Engineered listeria and methods of use thereof

Publications (1)

Publication Number Publication Date
ES2532942T3 true ES2532942T3 (es) 2015-04-06

Family

ID=38475431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07752174.8T Active ES2532942T3 (es) 2006-03-01 2007-03-01 Listeria obtenida por ingeniería genética y métodos de uso de la misma

Country Status (8)

Country Link
EP (2) EP2860253B1 (https=)
JP (1) JP5347135B2 (https=)
DK (1) DK1991263T3 (https=)
ES (1) ES2532942T3 (https=)
GB (1) GB2451014B (https=)
PT (1) PT1991263E (https=)
SI (1) SI1991263T1 (https=)
WO (1) WO2007103225A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20110129499A1 (en) * 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP5977737B2 (ja) * 2010-05-23 2016-08-24 アデュロ バイオテック 癌の補助薬物療法でリステリアを使用する方法および組成物
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
KR20150084033A (ko) * 2012-11-06 2015-07-21 아두로 바이오테크, 인코포레이티드 조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
SG10201700916SA (en) * 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
CA2982543A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
EP3313418B1 (en) 2015-06-26 2024-03-13 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
CA3003097A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
US11155617B2 (en) 2016-06-23 2021-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
US20190369087A1 (en) 2016-12-23 2019-12-05 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
CA3055203A1 (en) 2017-03-03 2018-09-07 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2019118760A1 (en) * 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
AU2018395525B2 (en) 2017-12-29 2023-09-14 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
JP7571063B2 (ja) 2019-06-22 2024-10-22 シーラス コーポレイション 生物学的流体の処理を実施するシステム及び方法
CN114269394A (zh) 2019-06-28 2022-04-01 塞鲁斯公司 用于实现生物流体处理装置的系统和方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551784B2 (en) 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
ATE254931T1 (de) 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
AU2001255196A1 (en) * 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004503512A (ja) 2000-06-09 2004-02-05 アメリカ合衆国 免疫複合体の抗腫瘍活性を改善し、かつ、毒性を低減するリンカーのpeg化
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1708741B1 (en) * 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
PT2942391T (pt) * 2004-08-13 2018-10-09 Univ Pennsylvania Métodos de produção de vacinas não resistentes aos antibióticos
WO2006017857A2 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines

Also Published As

Publication number Publication date
GB2451014A (en) 2009-01-14
DK1991263T3 (en) 2015-03-30
EP1991263B8 (en) 2015-02-25
JP2009528065A (ja) 2009-08-06
GB2451014B (en) 2010-12-29
EP2860253A2 (en) 2015-04-15
EP1991263B1 (en) 2014-12-24
SI1991263T1 (sl) 2015-03-31
JP5347135B2 (ja) 2013-11-20
GB0817892D0 (en) 2008-11-05
HK1203557A1 (en) 2015-10-30
PT1991263E (pt) 2015-03-03
EP1991263A2 (en) 2008-11-19
WO2007103225A2 (en) 2007-09-13
EP2860253B1 (en) 2018-08-01
EP2860253A3 (en) 2015-04-22
WO2007103225A3 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
ES2532942T3 (es) Listeria obtenida por ingeniería genética y métodos de uso de la misma
US7935804B2 (en) Engineered Listeria and methods of use thereof
US20070207171A1 (en) Engineered listeria and methods of use thereof
US9663557B2 (en) Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US9511129B2 (en) Facultatively attenuated bacterial species and methods of preparation and use thereof
WO2007117371A2 (en) Engineered listeria and methods of use thereof
EP2576791B1 (en) Methods and compositions using listeria for adjuvant treatment of cancer
US20110287055A1 (en) Compositions comprising prfa* mutant listeria and mehtods of use thereof
CN101198358B (zh) 具有增强的逃出内体能力的重组bcg菌株
US20120121643A1 (en) Engineered listeria and methods of use thereof
US10526609B2 (en) Protein expression enhancer sequences and use thereof
US10293039B2 (en) Attenuated Listeria monocytogenes mutant as a vaccine vector for the delivery of exogeneous antigens
HK1203557B (en) Engineered listeria and methods of use thereof
US10226521B2 (en) Genetically modified Yersinia as vaccines against Yersinia species
US10925945B2 (en) Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof